SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Respiratory Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Zacà, V.
Right arrow Articles by Dei Cas, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zacà, V.
Right arrow Articles by Dei Cas, L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade

Valerio Zacà

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy

Marco Metra

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy, metramarco{at}libero.it

Rossella Danesi

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy

Carlo Lombardi

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy

Giulia Verzura

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy

Livio Dei Cas

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy

Pulmonary arterial hypertension (PAH) is a rare but well-known cardiovascular condition potentially associated with human immunodeficiency virus (HIV) infection and is currently recognized to be one of the most ominous noninfectious HIV complications. Although there is no clear evidence supporting the use of any medication for the treatment of HIV-related PAH, many of the currently available agents have been shown to exert some clinical benefits HIV-PAH patients. To date, no data are available regarding the potential effects of sitaxsentan, a selective endothelin type-A receptor antagonist, in this peculiar patient population. We report the case of a successful switch to sitaxsentan in a HIV-infected patient with PAH initially receiving bosentan who developed a late treatment-related side-effect.

Key Words: HIV infection • pulmonary arterial hypertension • endothelin receptor antagonists • sitaxsentan

Therapeutic Advances in Respiratory Disease, Vol. 3, No. 1, 11-14 (2009)
DOI: 10.1177/1753465808101549
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement